Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Xspray Pharma in connection with its rights issue
Mandate

Vinge has advised Xspray Pharma in connection with its rights issue

March 26, 2026 Capital Markets and Public M&A

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.

Xspray is a pharmaceutical company that specializes in using its patented HyNap-technology to develop improved versions of existing protein kinase inhibitors (PKIs) for cancer treatment.

Vinge’s team consisted of Dain Hård Nevonen, Louise Nässén, Amanda Sandström and Nora Karlsson (Capital Markets and Public M&A).

Related

Vinge advises IK Partners and Selatek in connection with the acquisition of Jamo Sikring

 Vinge advises IK Partners and their portfolio company Selatek AB ("Selatek") in connection with the acquisition of JAMO SIKRING A/S ("Jamo Sikring"), a Danish specialist in the installation, maintenance and ongoing inspection of fire protection systems. The acquisition marks Selatek's establishment of operations in Denmark and strengthens the group's position in fire safety and security services in the Nordics.
August 21, 2026

Vinge advises Xamera Group on the acquisition of the Finnish company Integrify

 Xamera Group, partly owned by Helix Kapital, has acquired all the shares in the Finnish company Integrify, a leading Finnish provider of technology-focused and hire-purchase-based skills provision to the industrial, defence and tech sectors.
August 20, 2026

Vinge advises Advania on the acquisition of Cortex Consult A/S

 Vinge has advised Advania on the acquisition of Cortex Consult A/S, a Danish IT services company with more than 25 years of experience in managed IT services, cloud solutions and cybersecurity for customers across a range of industries.
August 18, 2026